Dinesh de Alwis

518 total citations
19 papers, 368 citations indexed

About

Dinesh de Alwis is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Dinesh de Alwis has authored 19 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 6 papers in Immunology and 3 papers in Genetics. Recurrent topics in Dinesh de Alwis's work include Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (8 papers) and Virus-based gene therapy research (3 papers). Dinesh de Alwis is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (8 papers) and Virus-based gene therapy research (3 papers). Dinesh de Alwis collaborates with scholars based in United States, Spain and France. Dinesh de Alwis's co-authors include Tomoko Freshwater, Anna Kondic, Julie A. Stone, Malidi Ahamadi, Rik de Greef, Lokesh Jain, Mallika Lala, Elliot Chartash, Vikram Sinha and Kapil Mayawala and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Dinesh de Alwis

18 papers receiving 364 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dinesh de Alwis United States 9 276 109 69 44 33 19 368
Lewis Au United Kingdom 11 267 1.0× 86 0.8× 81 1.2× 88 2.0× 37 1.1× 30 396
Z. Tomasevic Serbia 10 150 0.5× 70 0.6× 40 0.6× 46 1.0× 89 2.7× 24 306
Д. В. Комов Russia 7 158 0.6× 106 1.0× 28 0.4× 25 0.6× 81 2.5× 21 248
Nethanel Asher Israel 12 334 1.2× 115 1.1× 70 1.0× 117 2.7× 12 0.4× 31 454
Mitchell S. von Itzstein United States 11 222 0.8× 60 0.6× 101 1.5× 42 1.0× 29 0.9× 32 344
Andriy Krendyukov Germany 13 270 1.0× 181 1.7× 22 0.3× 25 0.6× 15 0.5× 53 417
Débora S. Bruno United States 12 215 0.8× 77 0.7× 128 1.9× 51 1.2× 21 0.6× 45 352
Daniel E. Meyers Canada 15 412 1.5× 86 0.8× 179 2.6× 108 2.5× 34 1.0× 41 618
E. Grigoryeva United States 4 364 1.3× 129 1.2× 71 1.0× 97 2.2× 14 0.4× 5 393

Countries citing papers authored by Dinesh de Alwis

Since Specialization
Citations

This map shows the geographic impact of Dinesh de Alwis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dinesh de Alwis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dinesh de Alwis more than expected).

Fields of papers citing papers by Dinesh de Alwis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dinesh de Alwis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dinesh de Alwis. The network helps show where Dinesh de Alwis may publish in the future.

Co-authorship network of co-authors of Dinesh de Alwis

This figure shows the co-authorship network connecting the top 25 collaborators of Dinesh de Alwis. A scholar is included among the top collaborators of Dinesh de Alwis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dinesh de Alwis. Dinesh de Alwis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Alwis, Dinesh de, Francesco Borriello, Eric Carlin, et al.. (2025). 89. First-in-human study of a novel half-life extended monoclonal antibody (GB-0669) against SARS-CoV2 and related sarbecoviruses. Open Forum Infectious Diseases. 12(Supplement_1). 1 indexed citations
2.
Cohen, Graham, Bernardo L. Rapoport, Paul Ruff, et al.. (2024). Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. PLoS ONE. 19(11). e0309778–e0309778.
3.
Parra‐Guillén, Zinnia P., Kapil Mayawala, Sara Zalba, et al.. (2023). Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically‐Based Modeling. Clinical Pharmacology & Therapeutics. 114(3). 623–632. 9 indexed citations
4.
Mayawala, Kapil & Dinesh de Alwis. (2022). Dose Finding in Oncology: What is Impeding Coming of Age?. Pharmaceutical Research. 39(8). 1817–1822. 1 indexed citations
5.
Zalba, Sara, Marı́a J. Garrido, Pedro Berraondo, et al.. (2021). Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. Cancers. 13(20). 5049–5049. 3 indexed citations
6.
Parra‐Guillén, Zinnia P., Tomoko Freshwater, Youfang Cao, et al.. (2021). Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration. Frontiers in Pharmacology. 12. 705443–705443. 10 indexed citations
7.
Kumar, Rukmini, Lakshmanan Jagannathan, Li Liu, et al.. (2021). Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response. CPT Pharmacometrics & Systems Pharmacology. 10(7). 684–695. 13 indexed citations
8.
Zalba, Sara, Virginia Belsúe, Brian Topp, et al.. (2021). Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1. British Journal of Cancer. 124(7). 1275–1285. 6 indexed citations
9.
Prohn, Marita, Anders Viberg, Da‐Lin Zhang, et al.. (2021). Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients. CPT Pharmacometrics & Systems Pharmacology. 10(3). 255–267. 18 indexed citations
10.
Jacobs, Conrad, Bernardo L. Rapoport, Graham Cohen, et al.. (2021). Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma. Cancer Research. 81(13_Supplement). CT143–CT143. 8 indexed citations
11.
Topp, Brian, et al.. (2020). Abstract PO-131: Inter-tumoral heterogeneity of progressive disease in melanoma patients treated with pembrolizumab. Cancer Research. 80(21_Supplement). PO–131. 1 indexed citations
12.
Lala, Mallika, Elliot Chartash, Shu‐Chih Su, et al.. (2020). Abstract CT042: Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients. Cancer Research. 80(16_Supplement). CT042–CT042. 20 indexed citations
13.
Stone, Julie A., Ellen Snyder, Leslie Lipka, et al.. (2019). Immunogenicity of pembrolizumab in patients with advanced tumors. Journal for ImmunoTherapy of Cancer. 7(1). 212–212. 44 indexed citations
14.
Lala, Mallika, Mengyao Li, Vikram Sinha, et al.. (2018). A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.. Journal of Clinical Oncology. 36(15_suppl). 3062–3062. 26 indexed citations
15.
Nayak, Satyaprakash, Oliver Sander, Nidal Al‐Huniti, et al.. (2018). Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use. Clinical Pharmacology & Therapeutics. 103(3). 378–383. 20 indexed citations
16.
Schwartz, Lawrence H., Seth Robey, David C. Turner, et al.. (2018). Correlation of survival outcomes with progression heterogeneity in patients (pts) treated with pembrolizumab (pembro).. Journal of Clinical Oncology. 36(15_suppl). 3017–3017. 1 indexed citations
17.
Freshwater, Tomoko, Anna Kondic, Malidi Ahamadi, et al.. (2017). Evaluation of dosing strategy for pembrolizumab for oncology indications. Journal for ImmunoTherapy of Cancer. 5(1). 43–43. 182 indexed citations
18.
Orrell, David, Damien M. Cronier, Lawrence M. Gelbert, et al.. (2011). Abstract 4918: Predicting the effect of drug combination schedules on xenograft growth using the Virtual Tumor. Cancer Research. 71(8_Supplement). 4918–4918. 3 indexed citations
19.
Burgess, Michael & Dinesh de Alwis. (2007). The True Face of the Revolution in Oncology Drug Development: A Personal Reflection. Current Clinical Pharmacology. 2(1). 31–35. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lewis Au Breakdown of academic impact, for papers by Z. Tomasevic Breakdown of academic impact, for papers by Д. В. Комов Breakdown of academic impact, for papers by Nethanel Asher Breakdown of academic impact, for papers by Mitchell S. von Itzstein Breakdown of academic impact, for papers by Andriy Krendyukov Breakdown of academic impact, for papers by Débora S. Bruno Breakdown of academic impact, for papers by Daniel E. Meyers Breakdown of academic impact, for papers by E. Grigoryeva
Rankless by CCL
2026